Dividends & Buybacks ·
Novo Nordisk provided an update on its share repurchase programme, which aims to repurchase up to DKK 15 billion in…
NVONovo Nordisk A S
Novo Nordisk provided an update on its share repurchase programme, which aims to repurchase up to DKK 15 billion in shares during a 12-month period starting 4 February 2026. Between 22 June and 26 June 2026, the company repurchased 7,250,000 B shares at an accumulated transaction value of DKK 2,098,848,921. Since the programme's inception on 4 February 2026, the company has repurchased a total of 22,009,179 B shares at an average price of DKK 268.02, totaling DKK 5,898,848,910. The company currently holds 39,194,480 B shares as treasury shares. Novo Nordisk is a global healthcare company specializing in diabetes and chronic disease treatments.